IONS

SEC source: 0000874015-24-000052 · edgardoc.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,059

Underlying: Common Stock · 32,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000052 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,635

Underlying: Common Stock · 27,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000051 · edgardoc.xml · derivative · entry 2

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,328

Underlying: Common Stock · 20,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000051 · edgardoc.xml · derivative · entry 1

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,338

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000050 · edgardoc.xml · derivative · entry 2

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,814

Underlying: Common Stock · 20,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000050 · edgardoc.xml · derivative · entry 1

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,482

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 8,387

Underlying: Common Stock · 2,625 shares

Expires not disclosed

F6 · security: Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 3

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 5,762

Underlying: Common Stock · 1,800 shares

Expires not disclosed

F6 · security: Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,661

Underlying: Common Stock · 20,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,290

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000059 · edgardoc.xml · derivative · entry 3

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,265

Underlying: Common Stock · 8,000 shares

Expires 2032-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000059 · edgardoc.xml · nonDerivative · entry 2

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,170

SEC source: 0000874015-24-000059 · edgardoc.xml · nonDerivative · entry 1

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000026 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 154

Underlying: Common Stock · 154 shares

Expires 2034-01-01

F2 · derivative.exercise_date: Grant on 01/02/2024 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000026 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000025 · edgardoc.xml · derivative · entry 1

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000024 · edgardoc.xml · derivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000023 · edgardoc.xml · derivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,580

Underlying: Common Stock · 116,580 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000022 · edgardoc.xml · derivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,200

Underlying: Common Stock · 43,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000021 · edgardoc.xml · derivative · entry 1

Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000020 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,200

Underlying: Common Stock · 43,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000019 · edgardoc.xml · derivative · entry 1

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000018 · edgardoc.xml · derivative · entry 1

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000017 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 3,500

Underlying: Common Stock · 3,500 shares

Expires 2034-01-01

F2 · derivative.exercise_date: Grant on 01/02/2024 to reporting person's spouse of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000017 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-23-000241 · edgardoc.xml · derivative · entry 9

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,525 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000241 · edgardoc.xml · nonDerivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,588

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-23-000241 · edgardoc.xml · nonDerivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,113

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000006 · edgardoc.xml · derivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,100 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000006 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,516

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.

SEC source: 0000874015-24-000006 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,616

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000005 · edgardoc.xml · derivative · entry 3

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,225 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000005 · edgardoc.xml · nonDerivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,086

F1 · kind: Represents a "net exercise" of outstanding stock options. The reporting person received 1,427 shares of common stock on net exercise of option to purchase 45,225 shares of common stock. Pursuant to the terms of the Company's 2011 Equity Incentive Plan, the Company withheld 43,798 shares of common stock underlying the option for payment of the exercise price and tax withholdings using the closing stock price on December 28, 2023 of $50.50.

SEC source: 0000874015-24-000005 · edgardoc.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000004 · edgardoc.xml · derivative · entry 3

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,482

Underlying: Common Stock · 11,500 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000004 · edgardoc.xml · nonDerivative · entry 2

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,999

F1 · kind: Represents a "net exercise" of outstanding stock options. The reporting person received 471 shares of common stock on net exercise of option to purchase 11,500 shares of common stock. Pursuant to the terms of the Company's 2011 Equity Incentive Plan, the Company withheld 11,029 shares of common stock underlying the option for payment of the exercise price and tax withholdings using the closing stock price on December 28, 2023 of $50.50.

SEC source: 0000874015-24-000004 · edgardoc.xml · nonDerivative · entry 1

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,028

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000241 · edgardoc.xml · derivative · entry 8

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,525

Underlying: Common Stock · 50,000 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000241 · edgardoc.xml · nonDerivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,588

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.07 to $50.75 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-23-000241 · edgardoc.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,588

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000242 · edgardoc.xml · derivative · entry 3

O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,825 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000242 · edgardoc.xml · nonDerivative · entry 2

O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,355

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.30 to $51.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.

SEC source: 0000874015-23-000242 · edgardoc.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000241 · edgardoc.xml · derivative · entry 7

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,525

Underlying: Common Stock · 25,113 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000241 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,588

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.30 to $51.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.

SEC source: 0000874015-23-000241 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000240 · edgardoc.xml · derivative · entry 3

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000240 · edgardoc.xml · nonDerivative · entry 2

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,052

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.30 to $51.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.

SEC source: 0000874015-23-000240 · edgardoc.xml · nonDerivative · entry 1

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000236 · edgardoc.xml · derivative · entry 6

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,113 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.